Abstract:ObjectivePreeclampsia is a condition arising from poor placentation and manifests itself as hypertension and proteinuria later in pregnancy. There are currently no specific laboratory based tests to diagnose preeclampsia for timely management or use of interventions. As a result, preeclampsia is a leading cause of preterm birth as well as maternal and fetal death. Our objective is to develop a serological protein assay to allow early recognition and referral of preeclamptic patients to Maternal Fetal Medicine specialists.Study DesignCandidate biomarkers were revealed by ensemble analysis of gene expression and proteomics profiling of preeclampsia samples. Biomarkers were further qualified with enzyme-linked immunosorbent assays (ELISA) using serum samples from 33 preeclampsia subjects and 31 pregnant controls matched by parity, ethnicity, and gestational age (range 24-40 weeks). A five-protein serological panel, comprised of both novel and investigational proteins, was constructed by the application of a genetic algorithm optimized for its ability to accurately diagnose preeclampsia as defined by the area under the receiving operating characteristic curve.ResultsWe observed better clustering and separation between samples from preeclamptic and non-preeclamptic patients compared to previously described, investigational diagnostic tests. Separation between patients groups was more pronounced earlier in gestational age.ConclusionWe have identified a serological protein panel capable of diagnosing both early and late onset preeclampsia. Further characterization of the novel panel analytes yielded mechanistic insights in preeclampsia, therefore, explaining the observed sensitivity and specificity across gestational ages. Future prospective validation can drive the translation of our serological panel into practical bedside clinical utilities for preeclampsia care. The work was supported by grants from the March of Dimes and Stanford University Spark Program. ObjectivePreeclampsia is a condition arising from poor placentation and manifests itself as hypertension and proteinuria later in pregnancy. There are currently no specific laboratory based tests to diagnose preeclampsia for timely management or use of interventions. As a result, preeclampsia is a leading cause of preterm birth as well as maternal and fetal death. Our objective is to develop a serological protein assay to allow early recognition and referral of preeclamptic patients to Maternal Fetal Medicine specialists. Preeclampsia is a condition arising from poor placentation and manifests itself as hypertension and proteinuria later in pregnancy. There are currently no specific laboratory based tests to diagnose preeclampsia for timely management or use of interventions. As a result, preeclampsia is a leading cause of preterm birth as well as maternal and fetal death. Our objective is to develop a serological protein assay to allow early recognition and referral of preeclamptic patients to Maternal Fetal Medicine specialists. Study DesignCandidate biomarkers were revealed by ensemble analysis of gene expression and proteomics profiling of preeclampsia samples. Biomarkers were further qualified with enzyme-linked immunosorbent assays (ELISA) using serum samples from 33 preeclampsia subjects and 31 pregnant controls matched by parity, ethnicity, and gestational age (range 24-40 weeks). A five-protein serological panel, comprised of both novel and investigational proteins, was constructed by the application of a genetic algorithm optimized for its ability to accurately diagnose preeclampsia as defined by the area under the receiving operating characteristic curve. Candidate biomarkers were revealed by ensemble analysis of gene expression and proteomics profiling of preeclampsia samples. Biomarkers were further qualified with enzyme-linked immunosorbent assays (ELISA) using serum samples from 33 preeclampsia subjects and 31 pregnant controls matched by parity, ethnicity, and gestational age (range 24-40 weeks). A five-protein serological panel, comprised of both novel and investigational proteins, was constructed by the application of a genetic algorithm optimized for its ability to accurately diagnose preeclampsia as defined by the area under the receiving operating characteristic curve. ResultsWe observed better clustering and separation between samples from preeclamptic and non-preeclamptic patients compared to previously described, investigational diagnostic tests. Separation between patients groups was more pronounced earlier in gestational age. We observed better clustering and separation between samples from preeclamptic and non-preeclamptic patients compared to previously described, investigational diagnostic tests. Separation between patients groups was more pronounced earlier in gestational age. ConclusionWe have identified a serological protein panel capable of diagnosing both early and late onset preeclampsia. Further characterization of the novel panel analytes yielded mechanistic insights in preeclampsia, therefore, explaining the observed sensitivity and specificity across gestational ages. Future prospective validation can drive the translation of our serological panel into practical bedside clinical utilities for preeclampsia care. The work was supported by grants from the March of Dimes and Stanford University Spark Program. We have identified a serological protein panel capable of diagnosing both early and late onset preeclampsia. Further characterization of the novel panel analytes yielded mechanistic insights in preeclampsia, therefore, explaining the observed sensitivity and specificity across gestational ages. Future prospective validation can drive the translation of our serological panel into practical bedside clinical utilities for preeclampsia care. The work was supported by grants from the March of Dimes and Stanford University Spark Program.

Integrating Multiple ‘omics’ Analyses Identifies Serological Protein Biomarkers for Preeclampsia

Serum peptidomic screening identified circulating peptide biomarkers predictive for preeclampsia

642: Transcriptomics and Proteomics Ensemble Analyses Reveal Serological Protein Panel for Preeclampsia Diagnosis

Abstract 11949: Novel First-Trimester Serum Biomarkers for Early Prediction of Preeclampsia

Distinct cytokine profiles in patients with preeclampsia

A cross-sectional analysis of syncytiotrophoblast membrane extracellular vesicles-derived transcriptomic biomarkers in early-onset preeclampsia

Integration of Single-Cell Sequencing and Transcriptomic Analysis to Identify Novel Diagnostic Biomarkers for Preeclampsia and Explore Changes in Immune Cell Interactions

Fibrinogen beta chain may be a potential predict biomarker for pre-eclampsia: A preliminary study

Integrated Proteomic and N-Glycoproteomic Profiling of Placental Tissues of Patients with Preeclampsia.

Multiplex Analysis of Circulating Maternal Cardiovascular Biomarkers Comparing Preeclampsia Subtypes

Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia

Serum markers of pre-eclampsia identified on proteomics.

Prediction of Differentially Expressed Genes and a Diagnostic Signature of Preeclampsia Via Integrated Bioinformatics Analysis

Potential Protein Biomarkers For Preeclampsia

Single-Cell RNA Sequencing and Microarray Analysis Reveal the Role of Lipid-Metabolism-Related Genes and Cellular Immune Infiltration in Pre-Eclampsia and Identify Novel Biomarkers for Pre-Eclampsia

Potential Of Immune-Related Genes As Biomarkers For Diagnosis And Subtype Classification Of Preeclampsia

Proteomic Analysis Reveals Differential Protein Expression in Placental Tissues of Early-Onset Preeclampsia Patients

Serum Protein Marker Panel for Predicting Preeclampsia.

Bioinformatics Methods in Biomarkers of Preeclampsia and Associated Potential Drug Applications

Identification and validation of an angiogenesis-related signature associated with preeclampsia by bioinformatic analysis

IGFBP1 and Routine Laboratory Indicators for Early Prediction of Pre-Eclampsia in Chinese Population